Cortechs.ai announces official support of Nuance PowerScribe 360 in NeuroQuant®

Collaboration provides automatic generation of NeuroQuant volumetric data into radiology reports using PowerScribe® 360

(San Diego, CA) November 30, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that NeuroQuant now supports Nuance PowerScribe ® 360, a technology collaboration will support accurate and automatic field population of PowerScribe 360 reports with NeuroQuant’s volumetric MRI data.

Hospitals, clinics, imaging and research centers worldwide will benefit from this expanded capability, which provides automatic and flexible data integration of NeuroQuant’s 3D T1 MRI brain structure measurements, with Nuance PowerScribe 360, the industry’s most trusted and widely used real-time radiology reporting solution.

“We are excited to work with Nuance to provide our customers with streamlined reporting of NeuroQuant data through PowerScribe 360,” said Guri Stark, Cortechs.ai’ CEO. “We believe this collaboration will significantly benefit many physicians and clinicians using NeuroQuant in increasing productivity and reducing transcription and data entry errors, allowing them to deliver better patient care.”

For more information about using PowerScribe with NeuroQuant, please visit Cortechs.ai at Booth 1861 (Hall A, South) during Radiological Society of North America’s (RSNA) 2015 Annual Meeting (Nov. 29 – Dec. 4, McCormick Place, Chicago).

About Cortechs.ai                                                                                                                                                         

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.

Insights

02/09/2025

NeuroQuant® MS:  Advancing Precision in Multiple Sclerosis

Dr. Suzie Bash discusses NeuroQuant MS, noting its ability to segment plaques, analyze volume, and track lesion burden for assessing disease progression

02/09/2025

Epilepsy Care with NeuroQuant Seizure: The Power of Quantifying Hippocampal Asymmetry

Accurate imaging of the hippocampus is crucial for effective diagnosis and treatment planning in TLE, with structural abnormalities linked to seizure onset

02/06/2025

Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

This milestone marks the first clinical use of OnQ Prostate’s RSI technology to guide focal therapy, improving lesion localization and targeting for urologists.
Scroll to Top